3 Monster Stocks to Hold for the Next 10 Years

The article highlights three long-duration growth opportunities: robotaxis, nuclear SMRs, and SpaceX’s expected IPO, with cited market sizes of roughly $10 trillion for robotaxis and nuclear energy and a $1.5 trillion to $2 trillion valuation for SpaceX. It is constructive on Tesla, Rivian, NuScale Power, and SpaceX, but the piece is largely promotional/analytical rather than new company-specific financial disclosure. The biggest concrete catalyst mentioned is Rivian’s $1.25 billion Uber order for as many as 50,000 vehicles.

Analysis

The important second-order setup is not that these themes are “big,” but that they sit at very different points on the commercialization curve. TSLA and UBER are nearer-term monetization vehicles because they can compound existing platforms into autonomous services, while RIVN is a convexity bet on being acquired into a fleet model or securing a strategic channel before scale disadvantage becomes fatal. The market is likely underpricing the difference between owning the operating system of autonomy versus the hardware wrapper around it.

For UBER, the strategic risk is that fleet economics get compressed as robotaxi supply scales: if autonomous miles become abundant, dispatch platforms may migrate from demand aggregation to a lower-margin routing layer. That said, in the next 12-24 months Uber benefits from being the easiest distribution partner for OEMs that lack consumer reach, so it can monetize autonomy before fully owning it. The real battleground is capex efficiency—any company with a high asset-light multiple could rerate downward if the market starts capitalizing robotaxi as a utility rather than a growth platform.

SMR is a different trade entirely: the market is beginning to price a nuclear renaissance, but the capital structure and execution path still look like venture capital, not infrastructure. The key risk is timeline slippage; every year of delay increases financing dilution and weakens the multiple, while successful permitting creates a sharp repricing because the addressable market is long-duration and policy-backed. In other words, SMR is more sensitive to regulatory milestones than to operating metrics over the next 6-18 months.

The contrarian miss is that the headline “trillion-dollar market” framing may actually be bearish for near-term entry points: it invites crowded long-only positioning into names with binary execution risk and opaque terminal economics. SpaceX is especially tricky; the optionality is enormous, but the public market will likely overpay for future narratives before it can underwrite cash flow durability. The better expression may be relative value: own the beneficiaries with clearer revenue conversion, and fade the most narrative-rich IPO exposure if it prices at a premium to realizable 3-year earnings power.

Key Decisions for Investors

• Long TSLA vs. RIVN over 6-12 months: TSLA has the cleaner path to autonomous monetization and balance-sheet support; RIVN offers higher upside but materially higher dilution and execution risk. Prefer TSLA on pullbacks; only own RIVN as a small convexity position.
• Buy UBER on weakness into any autonomous partnership headline over 3-6 months: the market may underappreciate that Uber can monetize robotaxi adoption before the OEM winners are fully identified. Stop if the narrative shifts toward direct-to-consumer autonomy bypassing aggregators.
• Treat SMR as a catalyst trade, not a compounder: consider a smaller tactical long only ahead of permitting/customer milestones over the next 6-12 months, with tight risk controls. If milestones slip, expect multiple compression to be sharper than fundamentals would imply.
• If SpaceX IPOs at the upper end of the range, prefer waiting for the first 30-60 trading days rather than chasing day-one enthusiasm. The entry risk/reward improves only after lockup, guidance clarity, and secondary demand are visible.
• Relative-value pair: long the most tangible autonomy beneficiary basket (TSLA/UBER) against the most narrative-dependent long-duration bets (RIVN/SMR) to isolate commercialization risk from theme beta.